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Aim: To demonstrate the efficacy of intravitreal injection of ranibizumabe in the treatment 
of patients with central retinal ocussion. Material and methods: For this material there were taken to be stuided 11 patients for the 
period from January 2012 to June 2013 who were with the retinal central vein blocking and were treated with intravitreal injection 
of ranibizumabi with the dose form 0.5 mlg. this was done in order to see how it reacted the macular edema after injections with 
ranibizumab and because of this it was measured vizus in the first week, first month, second month, third month, then every three 
months, and then until a full year. Patients taken for this study were selected from over 55 years, where the process of blocking of 
the central vein has happened at least three months in advance. Results: From our observations resulted that the growth of vezus 
was important and was reflected especially in the first week. Seven out of 11 patients felt improved the day after the examination, 
continuing to improve the positivity until the end of the first week and in the seventh week until the end of the second month. The 
improvment of vizus for the 11 cases was accidentally with an average of 4-5/10 N. This expressed in their final outcome after 12 
months observation. Conclusions: The ranibizuma intravitreal application in the treatment of patients with central retinal okuzion 
turns to be an efficient method. Intravitreal application of ranibizumabes (lucentis) turns out to be positive and for the 
consequences of blocking the VCR since in all applicable cases there is no result of an increased ocular tension. Study notes 
turbulence of vitreal improvement or macular degenerations or in cases in which patients except the blocking of the vein had these 
other issues, too. 
  
 Aim of the Study  
 The aim of this study is to demonstrate and evaluate the efficacy of intravitreal injection of 
ranibizumabe treatment of patients with central retinal ocussion. 
 In this paper we present our cases for the period from January 2012 to June 2013 for the treatment of the 
retinal central vein blocking with intravitreal injection of ranibizumabi with the dose form 0.5 mlg.  
 For these patients we have measured the correction for far and near, light sensitivity (contrast), have 
taken recent photos of the eye and angiography with flurosein as well as we have estimated the flow (leakage). 
All cases were followed for a period of 12 months.  
 Material and methods  
 In a manner referred to above, 11 eyes were studied of 11 patients with blockage of central retinal vein 
who were treated with travitreal injections of ranibizumab, this was done in order to see how it reacted the 
macular edema after injections of ranibizumab. We measured vizus in the first week, first month, second month, 
third month, then every three months, and then until a full year.  
 So we made 7 measurements at different times for each patient. We measured this view as for a large 
and close watching. For five of the patients we used OCT, but this examination is not carried out by us, because 
there is no such apparatus here. Patients were examined and marked as biomicroscope examinations (Slit-lamp), 
with the aplanacion Goldman tonometer.  
 Patients taken for this study were selected from over 55 years, where the process of blocking of the 
central  vein has happened at least three months in advance and when the declineof vezus  was to 1/10 of it. Also 
we have marked macular edema, diabetic retinopathy, the patients had or not cataract, glaucoma, have been 
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operated (surgery) or not, have had iris vascularization or not and the same notes were redrawn after three 
months from the first examination. The importance was paid to the use of drugs, before, during and after this 
episode. To our patients whose first injection is performed was also taken the first sidita, and other injections 
were listed according to the time in which they were conducted. In the following day, patients were asked for 
their sense of improving the visibility and pain.  
 Procedure   
 Local anesthesia with dicain, the preparations of the field with betadine, a drop of vigamox, 0.5mgl 
intravireali injection of ranibizumab in terms of the parsplana infero quandrant temporal 3.5-4mm from limbus. 
After injection we have reused two drops vogamox and we had given as a treatment tobradex 4 times a day of 1 
drop after injection. These injections were repeated when we had a persistence of macular edema or worsening 
of the vezus, these patients were subsequently treated according to the protocol. 
 Results 
Number of patients 11 
Age 65 +_10 
Sex (Female/Male) 5/6 





Vizus 1/10 normal 
 From our observations resulted that the growth of vezus  was important and was reflected especially in 
the first week. Seven out of 11 patients felt improved the day after the examination, continuing to improve the 
positivity until the end of the first week and in the seventh week until the end of the second month. The 
improvment of vizus for the 11 cases was accidentally with an average of 4-5/10 N. This expressed in their final 
outcome after 12 months observation.  Below we present a graphical distribution of cases treated.  
Table of data (measurements performed after any given period) 
Rastet/Vizusi Dita e parë Pas injeksionit Javën e pare Muaji 3 Muaji 6 Muaji 9 Muaji 12
1 (Mosha 63  ) 0.08 N 2/10 N 4/10 N 2/10 N 3/10 N 4/10 N 5/10 N
2 (Mosha 57 ) 0.05 N 3/10  N 3/10 N 3/10 N 4/10 N 3/10 N 3/10 N
3 (Mosha 60 ) 0.02 N 2/10N 3/10 N 3/10 N 3-4/10 N 4/10 N 3-4/10 N
4 (Mosha 62 ) 0.04 N 1/10 N 1/10 N 2/10 N 1/10 N 2/10 N 2/10 N
5 (Mosha 65  ) 0.07 N 2/10 N 3/10 N 4/10 N 4/10 N 4/10 N 4/10 N
6 (Mosha  59 ) 0.08 N 3/10 N 2/10 N 3/10 N 3/10 N 3-4/10 N 3-4/10 N
7 (Mosha  67 ) 0.05 N 3/10 N 2/10N 2/10 N 3/10 N 4/10 N 4/10 N
8 (Mosha  60 ) 0.03 N 2/10 N 1/10 N 2/10 N 2/10 N 3/10 N 3/10 N
9 (Mosha  62 ) 0.06 N 3/10 N 4/10 N 3/10 N 3/10 N 4/10 N 4/10 N
10 (Mosha  55 ) 0.04 N 1/10 N 2/10 N 2/10 N 4/10 N 3/10 N 3/10 N
11 (Mosha  66) 0.02 N 3/10 N 3/10 N 2/10 N 2/10 N 2/10 N 2/10 N  
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 Conclusions 
 1. The ranibizuma intravitreal application in the treatment of patients with central retinal okuzion turns 
to be an efficient method.  
 2. Intravitreal application of ranibizumabes (lucentis) turns out to be positive and for the consequences 
of blocking the VCR since in all applicable cases there is no result of an increased ocular tension.  
 3. Study notes turbulence of vitreal improvement or macular degenerations or in cases in which patients 
except  the blocking of the vein had these other issues. 
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